regorafenib (STIVARGA®)
Showing 1 - 25 of >10,000
Learn More About Long-Term Responses to Treatment With
Not yet recruiting
- Metastatic Colorectal Cancer
- Regorafenib (Stivarga, BAY73-4506)
-
Whippany, New JerseyBayer
Sep 1, 2023
Regorafenib Post-marketing Surveillance in Japan
Completed
- Gastrointestinal Stromal Tumors
- Regorafenib (Stivarga, BAY73-4506)
-
Multiple Locations, Japan(unnamed)
Mar 21, 2022
Learn More About Order of Different Treatments and Their Effects
Not yet recruiting
- Metastatic Colorectal Cancer
- Regorafenib (Stivarga, BAY73-4506)
- (no location specified)
Nov 13, 2023
Metastatic Colorectal Cancer (mCRC) Trial (JMT101, SG001, Irinotecan)
Not yet recruiting
- Metastatic Colorectal Cancer (mCRC)
- JMT101
- +3 more
- (no location specified)
Oct 13, 2023
Called ROCURS, to Learn About COVID-19 Related Outcomes in
Active, not recruiting
- Malignant Solid Tumors
- +2 more
- Non-TKIs
- +3 more
-
Whippany, New JerseyBayer
Feb 2, 2023
Microsatellite Stable Metastatic Colorectal Cancer Trial in Shanghai (Regorafenib, Toripalimab, High/low-dose radiotherapy)
Recruiting
- Microsatellite Stable Metastatic Colorectal Cancer
- Regorafenib
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 19, 2023
MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)
Not yet recruiting
- MSI-H Colorectal Cancer
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Aug 17, 2023
Metastatic Colorectal Cancer Trial in India (Regorafenib (Stivarga, BAY73-4506))
Active, not recruiting
- Metastatic Colorectal Cancer
- Regorafenib (Stivarga, BAY73-4506)
-
Hyderabad, Andhra Pradesh, India
- +12 more
Jan 13, 2023
Gastrointestinal Stromal Tumors Trial in Miami (Sunitinib, Regorafenib)
Recruiting
- Gastrointestinal Stromal Tumors
-
Miami, FloridaUniversity of Miami
Jan 3, 2023
Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)
Not yet recruiting
- Gastrointestinal Stromal Tumors
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2023
Carcinoma, Hepatocellular Trial in Germany, United States (Regorafenib(Stivarga, BAY73-4506), Pembrolizumab)
Active, not recruiting
- Carcinoma, Hepatocellular
- Regorafenib(Stivarga, BAY73-4506)
- Pembrolizumab
-
Los Angeles, California
- +6 more
Aug 15, 2022
Colo-rectal Cancer, Metastatic Cancer Trial in Besançon, Dijon, Montbéliard (Regorafenib, Cyclophosphamide, Capecitabine)
Active, not recruiting
- Colo-rectal Cancer
- Metastatic Cancer
- Regorafenib
- +3 more
-
Besançon, France
- +2 more
Jan 24, 2023
Hepatocellular Carcinoma Trial in Winston-Salem (TheraBionic, Regorafenib)
Recruiting
- Hepatocellular Carcinoma
- TheraBionic
- Regorafenib
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Oct 26, 2022
Called STAR-T to Learn More About Sequential Treatment With
Not yet recruiting
- Metastatic Colorectal Cancer (mCRC)
- Regorafenib (BAY73-4506, Stivarga®)
- +2 more
-
Whippany, New JerseyMany locations
Apr 21, 2023
Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)
Recruiting
- Hepatocellular Carcinoma (HCC)
-
Kaohsiung, Taiwan
- +4 more
Mar 14, 2023
Metastatic Pancreatic Adenocarcinoma Trial in Cleveland (Regorafenib, Gemcitabine Hydrochloride)
Terminated
- Metastatic Pancreatic Adenocarcinoma
- Regorafenib
- Gemcitabine Hydrochloride
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jun 1, 2022
Pancreas Cancer, Ovarian Cancer, Melanoma Trial in Rozzano (Regorafenib)
Completed
- Pancreas Cancer
- +6 more
-
Rozzano, Milan, ItalyIstituto Clinico Humanitas
Sep 9, 2022
Colorectal Cancer, Colorectal Cancer Metastatic Trial in United States (Pembrolizumab, Regorafenib)
Active, not recruiting
- Colorectal Cancer
- Colorectal Cancer Metastatic
- Pembrolizumab
- Regorafenib
-
Duarte, California
- +3 more
Aug 5, 2022
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Regorafenib
- +3 more
-
Kashiwa, Chiba, JapanNational Cancer Center Hospital East
May 23, 2022
Metastatic Colorectal Cancer Trial in France (Regorafenib then Trifluridine/Tipiracil, Trifluridine/Tipiracil then Regorafenib)
Recruiting
- Metastatic Colorectal Cancer
- Regorafenib then Trifluridine/Tipiracil
- Trifluridine/Tipiracil then Regorafenib
-
Bouge, Belgium
- +37 more
Dec 14, 2022
Colorectal Cancer Stage IV, No Evidence of Disease State Trial in Genova (Durvalumab Injection for intravenous use 500 mg vial
Recruiting
- Colorectal Cancer Stage IV
- No Evidence of Disease State
- Durvalumab Injection for intravenous use 500 mg vial solution for infusion
- Regorafenib 30 mg capsules
-
Genova, Liguria, ItalyIRCCS Ospedale Policlinico San Martino
May 16, 2022